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a  b  s  t  r  a  c  t
Eastern  Equine  Encephalitis  virus (EEEV)  is  a medically  important  pathogen  that  can  cause  severe
encephalitis  in  humans,  with  mortality  rates  ranging  from  30 to  80%.  Unfortunately  there  are  no  antivi-
rals  or  licensed  vaccines  available  for human  use,  and  laboratory  diagnosis  is  essential  to  differentiate
EEEV  infection  from  other  pathogens  with  similar  clinical  manifestations.  The  Arboviral  Diseases  Branch
(ADB)  reference  laboratory  at the  CDC  Division  of  Vector-Borne  Diseases  (DVBD)  produces  reference
antigens  used  in serological  assays  such  as  the  EEEV  immunoglobulin  M antibody-capture  enzyme-
linked  immunosorbent  assay  (MAC-ELISA).  However,  EEEV  is  classiﬁed  as a HHS  select  agent  and  requires
biosafety  level  (BSL)  three  containment,  limiting  EEEV  antigen  production  in  non-select  agent  and  BSL-2ntigen
mmunoglobulin M antibody-capture
nzyme-linked immunosorbent assay
MAC-ELISA)
eta-propiolactone
amma-irradiation
laboratories.  A recombinant  Sindbis  virus  (SINV)/EEEV  has  been  constructed  for use  under  BSL-2  con-
ditions and  is  not  regulated  as  a select  agent.  Cell  culture  production  of inactivated  EEEV antigen  from
SINV/EEEV  for use  in  the  EEEV  MAC-ELISA  is  reported  here.  Cell  culture  conditions  and  inactivation  pro-
cedures  were  analyzed  for  SINV/EEEV  using  a recently  developed  antigen  production  algorithm,  with  the
MAC-ELISA  as the  performance  indicator.
Published by Elsevier  B.V.  This is  an  open  access  article  under  the CC  BY license  (http://
creativecommons.org/licenses/by/4.0/).. Introduction
Eastern Equine Encephalitis virus (EEEV) is a medically impor-
ant mosquito-borne human and equine pathogen in North and
outh America (Grifﬁn, 2001; Wang et al., 2007; Weaver, 2001;
eaver et al., 1999). Primarily transmitted in an enzootic cycle
etween the mosquito vector Culiseta melanura and passerine birds
n freshwater, hardwood swamp habitats (Brault et al., 1999; Villari
t al., 1995; Wang et al., 2007; Weaver, 2001), transmission of EEEV
an occur via bridge vectors to dead-end hosts, such as humans,
orses, and other animals (Arrigo et al., 2008; Morris, 1988). There
re licensed vaccines for equines; however, no antivirals or licensed
accines are available for human use (Franklin et al., 2002; Wang
t al., 2007). Personal protection from mosquito bites is the only
ffective prevention strategy during times of active transmission,
nd treatment options are very limited.
EEEV is a member of the family Togaviridae, genus Alphavirus,
nd has been classiﬁed into EEEV (formerly North American) and
∗ Corresponding author.
E-mail address: bvv0@cdc.gov (C.H. Goodman).
ttp://dx.doi.org/10.1016/j.jviromet.2015.07.007
166-0934/Published by Elsevier B.V. This is an open access article under the CC BY licenMadariaga virus (formerly South American) (Powers et al., 2012).
Madariaga virus is not associated with severe human disease
(Aguilar et al., 2007; Arrigo et al., 2008; Tsai et al., 2002; Wang et al.,
2007; Weaver, 2001; Weaver et al., 1999); however, EEEV can cause
severe encephalitis in humans. The mortality rate of clinical EEEV
disease is 30–80% and up to 30% of patients who  survive have long-
term neurological sequelae (Johnson et al., 2011; Villari et al., 1995;
Wang et al., 2007). Clinical signs and symptoms usually begin with
high fever, headache, dizziness, and vomiting. Progression to severe
encephalitis with coma and paralysis can occur by day 2 of the dis-
ease (Wang et al., 2007). Although large EEEV outbreaks have been
reported, human infections are generally sporadic, with an aver-
age of six cases reported annually in the United States, primarily
along the east coast (www.cdc.gov/easternequineencephalitis/Epi.
html#map). Due to the sporadic nature of the disease and because
clinical symptoms of EEEV infection may  be similar to infections by
other pathogens, laboratory-based diagnosis is necessary to iden-
tify individuals infected with EEEV and to implement prevention
and control strategies (Arrigo et al., 2008).
EEEV infection is diagnosed in acute cases by virus isolation,
detection of viral RNA in serum or cerebrospinal ﬂuid, or sero-
logically by detection of EEEV-speciﬁc immunoglobulin M (IgM)
se (http://creativecommons.org/licenses/by/4.0/).
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ntibodies in an enzyme-linked immunosorbent assay (ELISA),
ith conﬁrmation by the plaque reduction neutralization test
PRNT) (Beaty et al., 1995; Johnson et al., 2011; Lambert et al.,
003). The CDC Division of Vector-Borne Diseases (DVBD) Arbovi-
al Diseases Branch (ADB) reference laboratory produces reagents
or arbovirus diagnostics for which there are no commercial assays
vailable, such as the EEEV IgM antibody-capture (MAC)-ELISA.
on-infectious antigens used in the MAC-ELISA are normally
erived from live virus that has been inactivated, with the serologi-
al reactivity preserved. An algorithm for production of inactivated
ntigens from arboviruses grown in cell culture was  recently devel-
ped and evaluated (Goodman et al., 2014). One method could not
e used for all of the arboviruses, but rather needed to be optimized
or each virus. The method used to inactivate the virus often had a
igniﬁcant effect on antigen reactivity, resulting in either antigen
egradation or increased reactivity.
EEEV strain NJ-60 is the prototype virus used previously to
roduce EEEV antigen. EEEV strains require biosafety level (BSL)
hree containment and are classiﬁed as HHS select agents (www.
electagents.gov/Select%20Agents%20and%20Toxins%20List.html).
onsequently, only select agent-registered laboratories with BSL-3
apacity are permitted to possess and work with EEEV strains.
owever, a recombinant Sindbis virus (SINV)/EEEV has been
onstructed in which genes expressing the EEEV immunogenic
tructural proteins have been inserted into the SINV backbone
Wang et al., 2007). SINV/EEEV can be used under BSL-2 conditions
nd is not regulated as a select agent. Previously, SINV/EEEV was
hown to be a comparable alternative challenge virus for use in the
RNT by public health laboratories with BSL-2 facilities (Johnson
t al., 2011). The use of SINV/EEEV to produce inactivated EEEV
ntigen needed to be assessed and is reported here. Of particular
oncern was the effect the inactivation procedure would have on
ntigen reactivity of the chimeric virus. Cell culture conditions
nd inactivation procedures were analyzed for SINV/EEEV using
he previously developed antigen production algorithm, with the
AC-ELISA as the performance indicator (Goodman et al., 2014).
. Materials and methods
.1. Viruses
Sindbis/Eastern Equine Encephalitis (N. American) chimeric
irus strain 796 (SINV/EEEV) was obtained from the University of
exas Medical Branch, Galveston, Texas (Wang et al., 2007).
.2. Tissue culture
Cell lines used in the growth curves were obtained at CDC DVBD.
frican green monkey kidney (Vero) cells, and baby hamster kid-
ey (BHK-21) clones 13 and 15 cells, were maintained at 37 ◦C
n Dulbecco’s Modiﬁed Eagle Medium (DMEM, Life Technologies,
rand Island, NY) with 8% fetal bovine serum (FBS, Atlas Biologicals,
ort Collins, CO), 1 mM  sodium pyruvate (Life Technologies), 27 mM
odium bicarbonate (Life Technologies), 0.1 mM gentamicin (Lonza,
alkersville, MD), and 1 uM amphotericin B (Sigma–Aldrich, St.
ouis, MO).
.3. Growth curves
Growth curves were performed in T150 cm2 cell culture ﬂasks
Corning Inc. Life Sciences, Tewksbury, MA), as previously described
Goodman et al., 2014). Brieﬂy, cells were infected at a multiplicity
f infection (MOI) of 0.001 PFU/cell. Following adsorption of virus
n 10 ml  of media at 37 ◦C for 1 h, cells were maintained in 60 ml
f media with 2% FBS (Atlas Biologicals). At 24 h intervals, 1.0 ml  of
upernatant was removed and stored at −70 ◦C until tested. Growthical Methods 223 (2015) 19–24
curves were carried out for 4 days until cytopathic effect (CPE)
reached ∼90–100%.
2.4. Virus titration
Virus titers were determined by 1% agarose double-overlay
plaque titration assay in Vero cells, as previously described (Beaty
et al., 1995). Plaques were visualized with second overlays applied
with 0.005% neutral red (Sigma–Aldrich) following incubation for
2 days. Virus titers were recorded as log10 PFU/ml.
2.5. IgM antibody-capture enzyme-linked immunosorbent assay
(MAC-ELISA)
The CDC MAC-ELISA was used, as previously described (Martin
et al., 2000). Positive-to-negative (P/N) ratios were determined,
where P was  deﬁned as the mean optical density (OD) of the pos-
itive control serum reacted on viral antigen and N was  deﬁned as
the mean OD of the negative control serum reacted on viral antigen.
Interpretation of test results were as follows: P/N < 2 = negative, P/N
2–3 = equivocal, P/N > 3 = positive. Additionally, for a test to be valid,
the mean OD of the sample serum reacted on viral antigen had to be
at least twice the mean OD of the sample serum reacted on normal
cell culture or suckling mouse brain antigen.
2.6. Viral antigen activity
Viral antigen activity was evaluated by the CDC MAC-ELISA, as
previously described (Martin et al., 2000; Goodman et al., 2014).
EEEV IgM positive and normal control reference sera were obtained
from the DVBD diagnostic laboratory. Brieﬂy, untreated live virus
or inactivated antigen was  serially diluted two-fold and reacted
against both constant EEEV IgM positive and normal control sera in
the MAC-ELISA. Virus-speciﬁc antigen activity (VSAA) was  deﬁned
as the optical density (OD) of viral antigen reacted against a con-
stant positive control serum; acceptable VSAA had an OD of >0.8.
Nonspeciﬁc background reactivity (NBR) was  deﬁned as the OD
of viral antigen reacted against a constant normal control serum;
acceptable NBR had an OD of <0.2. A satisfactory antigen was
deﬁned as that which had acceptable MAC-ELISA results, in which
both the VSAA and NBR were within acceptable OD ranges. The
highest antigen dilution with acceptable VSAA and NBR OD  ranges
was considered the working antigen dilution, and was a measure
of functional antigen concentration.
2.7. Virus production for inactivation and concentration analyses
The optimal virus cell culture type and day of harvest were
determined by the growth curves. A second batch was  then made
under the optimized conditions in four additional T150 cm2 ﬂask(s).
Supernatant was harvested and clariﬁed at 2400 × g for 10 min  at
4 ◦C, and stored at −70 ◦C with 20% FBS (Atlas Biologicals) until
further analysis.
2.8. Virus inactivation methods
2.8.1. Beta-propiolactone (BPL)
Virus cell culture supernatants were thawed in a 44 ◦C water
bath with intermittent shaking. Aliquots of 15 ml  were made and
BPL (CTC Organics, Atlanta, GA) was added at ﬁnal concentrations
ranging from 0.1% to 0.3%. The BPL-treated aliquots were incubated
for 24 h at 4 ◦C with moderate shaking on a refrigerated shaker
plate. Mock-treated control virus supernatants (no addition of BPL)
were incubated under the same conditions as the BPL-treated sam-
ples. Due to acidic BPL by-products, 7.5% sodium bicarbonate (Life
Technologies) was added intermittently to adjust the pH (French,
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cKinney, 1964). Following BPL treatment the samples were stored
t −70 ◦C until further analysis. For hydrolysis analysis, samples
ere treated with 0.2% BPL and incubated for 24 h at 4 ◦C with mod-
rate shaking. Following BPL treatment, material that underwent
ydrolysis was incubated at 37 ◦C for 2 h, and then placed at −70 ◦C
ntil further analysis.
.8.2. Gamma-irradiation
Gamma-irradiation was carried out at the CDC irradiation facil-
ty in Atlanta, GA using a cobalt-60 source with a 500 ml  volume
apacity. Based on previous experience inactivating alphaviruses,
amples were irradiated with 6 Mrad (Goodman et al., 2014). Sam-
les were maintained frozen on dry ice throughout shipping and the
reatment process. Untreated control virus supernatants remained
rozen without any exposure to gamma-irradiation.
.9. Antigen concentration
Antigen was concentrated after inactivation, as it had been
etermined empirically that antigen activity was  lost if it was  con-
entrated before inactivation. Inactivated cell culture supernatants
ere concentrated in Amicon Ultra-15 100 kDa Centrifugal Filter
evices (Millipore, Billerica, MA)  or Centricon Plus-70 100 kDa Cen-
rifugal Filter Devices (Millipore) at 3500 × g for 10–45 min  at 4 ◦C.
he ﬁnal volume was adjusted with 0.1 M trizma/BS buffer: 1.0 M
rizma pH 9.0 (Sigma–Aldrich) + borate saline solution pH 9.0 [1.5 M
odium chloride (Daigger, Vernon Hills, IL), 0.5 M boric acid (Fisher
cientiﬁc), 1.0N sodium hydroxide (Daigger)] to the desired con-
entration factor.
.10. Viability assays
Two procedures were used to evaluate virus inactivation, as
escribed previously (Goodman et al., 2014). Brieﬂy, plaque titra-
ion of BPL-treated or gamma-irradiated antigen was  performed
n duplicate in 6-well plates on Vero cells, beginning at neat con-
entration, with a lower limit of detection (LLOD) of 10 PFU/ml. In
ddition, 100 l of antigen was inoculated into duplicate T25 cm2
ell culture ﬂasks containing Vero cells and passaged once a week
or three weeks. Virus was considered inactivated if there was no
etectable titer by plaque titration and if there was  no detectable
PE in any of the three cell culture passages.
.11. Lyophilization
Inactivated antigen was lyophilized in 250 l aliquots in 2 ml,
3 mm Kimble serum vials (Kimble-Chase, Vineland, NJ) using
 freeze-dry system (Labconco, Kansas City, MO). Samples were
rozen at −70 ◦C overnight, and then lyophilized for 18 h at −30 ◦C,
hen 6 h at 30 ◦C.
.12. Antigen evaluation
A vial of lyophilized antigen was reconstituted and antigen per-
ormance was compared to reference suckling mouse brain antigen
SMB) in a panel of 12 archived de-identiﬁed EEEV IgM positive
erum samples which had previously been tested in the ADB diag-
ostic laboratory by the CDC-microsphere immunoassay (MIA) and
onﬁrmed by PRNT (Basile et al., 2013; Beaty et al., 1995; Johnson
t al., 2011). MIA  results do not measure IgM titer; therefore, neu-
ralization titers were used as a proxy to choose a range of high,
edium, and low EEEV positive samples. Per the CDC protocol,
amples were diluted 1:400 and tested in triplicate against the
nactivated SINV/EEEV cell culture antigen or EEEV SMB  antigen at
heir previously calculated working antigen dilutions of 1:40 andical Methods 223 (2015) 19–24 21
1:80, respectively. Optical densities were averaged, and positive-
to-negative (P/N) ratios were determined according to methods
described previously (Martin et al., 2000).
3. Results
SINV/EEEV growth curves were performed ﬁrst to determine
the optimal cell culture type to use for subsequent antigen pro-
duction. Next a small-scale batch of virus (two T150 ﬂasks) was
grown under the optimized cell culture conditions and used for
inactivation and concentration analyses. Once the inactivation and
concentration procedures were ﬁnalized, a large-scale batch of bulk
antigen was made. Final processing included making aliquots and
lyophilizing the antigen, and storage at −20 ◦C. Antigen perfor-
mance was  evaluated at each step in production by the MAC-ELISA,
and rated as acceptable or unacceptable based on VSAA and NBR.
The viability of the antigen was  assessed after initial inactivation
and at ﬁnal concentration to rule out residual infectivity. The cho-
sen inactivation method was the one that completely inactivated
the virus, had VSAA and NBR within the acceptable ranges, and had
the highest working antigen dilution compared to the mock-treated
or untreated virus.
3.1. SINV/EEEV growth curves
Virus was  inoculated into T150 cm2 ﬂasks containing Vero, BHK-
21c.13, or BHK-21c.15 cells at a MOI  of 0.001 and incubated for 4
days. Supernatant, 1 ml,  was  removed at 24 h time points and tested
by plaque titration and the EEEV MAC-ELISA. CPE was  seen begin-
ning on day 2 and was complete by days 3–4 (data not shown).
Titers peaked by day 1–2 and were between 8 and 9 log10 PFU/ml
in all cell types (Fig. 1). However, none of the aliquots tested by
the MAC-ELISA yielded acceptable VSAA despite the high titers
obtained (data not shown).
3.2. SINV/EEEV inactivation
It had been shown previously that the VSAA of some
alphaviruses increased after inactivation by BPL (French and
McKinney, 1964; Goodman et al., 2014). Therefore, as proof of
principle and despite the poor MAC-ELISA results, the remaining
supernatant from the three growth curve ﬂasks was collected on
day 5 and treated with 0.3% BPL. The VSAA of the BPL-inactivated
Vero cell culture supernatant increased and was acceptable out to a
1:3 dilution, but there was little increase of VSAA in the BHK-21c.13
and BHK-21c.15 cell culture supernatant (data not shown). Based
on these preliminary results, a small-scale batch of SINV/EEEV was
grown in Vero cells and harvested on day 3; this material was  used
for subsequent inactivation analyses.
Aliquots of SINV/EEEV supernatant from the small-scale mate-
rial were treated with 0.1, 0.15, 0.2, 0.25, and 0.3% BPL (Table 1A).
The SINV/EEEV VSAAs increased at all BPL concentrations com-
pared to mock-treated virus, which had VSAA below the acceptable
limit. All BPL concentrations completely inactivated the virus,
and SINV/EEEV treated with ≤0.25% BPL produced acceptable
MAC-ELISA results. These aliquots were then concentrated 50×
using Amicon Ultra-15 centrifugal ﬁlters (Table 1A). Concentrated
SINV/EEEV treated with ≤0.2% BPL had acceptable VSAA out to a
1:320 working antigen dilution; however, antigen treated with 0.1%
BPL remained infectious.
Based on the results from the SINV/EEEV small-scale inacti-
vation and concentration experiment described above, and those
from previous experiments that showed that 0.15% BPL was
perhaps the borderline concentration that would completely
inactivate alphaviruses, 0.2% BPL concentration was selected for
inactivation of the SINV/EEEV large-scale batch in order to assure
22 C.H. Goodman et al. / Journal of Virological Methods 223 (2015) 19–24
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Vig. 1. Growth of SINV/EEEV strain 796 in Vero, BHK-21c. 13, and BHK-21c.15 ce
nderlined conditions indicate the optimal cell type and harvest day based on perf
omplete inactivation (Table 1B). The BPL-treated SINV/EEEV large-
cale material was then concentrated 12× in a Centricon-70
entrifugal ﬁlter. The VSAA was acceptable out to a 1:20 working
ntigen dilution; however, during this scale-up process, the NBR
ose above the acceptable limit (Table 1B). An aliquot of BPL-treated
INV/EEEV was incubated at 37 ◦C for 2 h to assure complete hydrol-
sis of BPL. Hydrolyzed antigen NBR increased and VSAA decreased
ompared to the non-hydrolyzed antigen (data not shown). BPL,
herefore, was not considered a suitable inactivation method for
INV/EEEV antigen production.
Gamma  irradiation of SINV/EEEV small-scale material with 6
rad completely inactivated the virus. VSAA increased compared
able 1
INV/EEEV antigen reactivity in the EEEV MAC  ELISA following inactivation by BPL.
A. BPL treatment (small-scale)
Antigen dilution VSAA NBR VSAA NBR VSAA N
0.1% BPL 0.15% BPL 0.2% BPL 
1:2 1.995 0.156 2.151 0.478 1.960 0.5
1:4  1.192 0.075 1.357 0.103 1.157 0.0
1:8  0.812 0.045a 0.885 0.055 0.724 0.0
1:16  0.537 0.038 0.537 0.041 0.416 0.0
1:32  0.428 0.030 0.315 0.030 0.274 0.0
1:64  0.219 0.036 0.196 0.026 0.155 0.0
0.1%  BPL–50× 0.15% BPL – 50× 0.2% BPL – 50×
1:10 2.271 0.189 1.155 0.920 1.081 2.0
1:20  2.563 0.175 1.793 0.575 1.802 1.1
1:40  2.165 0.104 2.534 0.346 2.573 0.7
1:80  1.705 0.088 2.298 0.246 2.211 0.3
1:160  1.263 0.070 1.787 0.164 1.627 0.2
1:320 0.803 0.048c 1.200 0.089 0.953 0.1
B.  BPL treatment (large-scale)
Antigen dilution VSAA NBR 
0.2% BPL 
Unconcentrated 
1:10 0.547 0.064 
1:20  0.269 0.051 
1:40 0.160 0.036 
1:80  0.103 0.030 
1:160 0.066 0.031 
1:320 0.045 0.031 
SAA, virus-speciﬁc antigen activity; NBR, nonspeciﬁc background reactivity.
a OD readings in bold indicate the lowest dilution of antigen that yielded acceptable M
b ODs in bold underlined italics indicate the dilution of antigen that yielded acceptable
c OD readings in bold italics indicate the dilution of antigen that yielded acceptable VS-150 cm2 ﬂasks were inoculated with an MOI  of 0.001 and incubated for 4 days.
ce in the MAC-ELISA.
to untreated virus; acceptable MAC-ELISA results were obtained
out to a 1:8 working antigen dilution (Table 2A). The antigen was
then concentrated 25× in an Amicon Ultra-15 centrifugal ﬁlter, and
yielded acceptable MAC-ELISA results out to a 1:80 working anti-
gen dilution. The concentrated antigen remained non-infectious
(Table 2A).
Large-scale SINV/EEEV supernatant was  gamma-irradiated with
6 Mrad then concentrated 12× in a Centricon-70 centrifugal ﬁlter.
The concentrated antigen was not infectious, and had accept-
able MAC-ELISA activity out to a 1:40 working antigen dilution
(Table 2B). Therefore, gamma  irradiation was  selected as the inacti-
vation method for ﬁnal, scaled-up SINV/EEEV antigen production.
BR VSAA NBR VSAA NBR VSAA NBR
0.25% BPL 0.3% BPL Mock-treated
78 1.640 0.534 1.159 0.450b 0.215 0.029
99 0.999 0.072 0.713 0.083 0.208 0.025
45 0.593 0.039 0.437 0.039 0.118 0.022
38 0.346 0.031 0.277 0.032 0.063 0.021
29 0.197 0.030 0.204 0.025 0.027 0.024
24 0.123 0.024 0.129 0.025 0.022 0.022
 0.25% BPL – 50×
34 1.034 2.617
03 2.030 1.441
30 2.322 0.804
91 1.819 0.473
43 1.140 0.238
08 0.658 0.127
VSAA NBR
0.2% BPL
12× concentrated
2.009 0.487
1.117 0.245c
0.633 0.150
0.388 0.093
0.247 0.068
0.167 0.052
AC  ELISA results and was completely inactivated.
 VSAA, but unacceptable NBR.
AA and NBR, but which was  still infectious.
C.H. Goodman et al. / Journal of Virolog
Table  2
SINV/EEEV antigen reactivity in the EEEV MAC  ELISA following inactivation by
gamma-irradiation.
A. -treatment (small-scale)
Antigen dilution VSAA NBR VSAA NBR
6 Mrad Untreated
Neat 2.119 0.224 0.118 0.026
1:2 2.220 0.095 0.128 0.026
1:4 1.813 0.069 0.101 0.028
1:8 1.262 0.064a 0.052 0.029
1:16 0.707 0.054 0.036 0.026
1:32 0.407 0.051 0.029 0.032
6  Mrad – 25×
1:10 1.958 0.382
1:20 1.441 0.092
1:40 1.160 0.051
1:80 0.818 0.044
1:160 0.477 0.034
1:320 0.300 0.038
B. -treatment (large-scale)
Antigen dilution VSAA NBR VSAA NBR VSAA NBR
6 Mrad 6 Mrad 6 Mrad – 12X
Unconcentrated 12× concentrated Conc. – lyophilized
1:10 0.771 0.062 2.060 0.149 1.573 0.098
1:20  0.433 0.047 1.802 0.085 1.324 0.068
1:40  0.245 0.042 1.228 0.062 0.883 0.053
1:80 0.147 0.040 0.746 0.053 0.522 0.048
1:160 0.086 0.034 0.429 0.047 0.313 0.046
1:320 0.060 0.029 0.245 0.038 0.182 0.042
VSAA, virus-speciﬁc antigen activity; NBR, nonspeciﬁc background reactivity.
a OD readings in bold indicate the lowest dilution of antigen that yielded accept-
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Mble MAC ELISA results and was completely inactivated.
haded boxes indicate the inactivation condition(s) used for ﬁnal antigen produc-
ion.
liquots of 0.25 ml  were made of the ﬁnal product; the antigen
as then lyophilized, sealed, and stored at −20 ◦C. To test stabil-
ty of the ﬁnal product, one vial of the lyophilized antigen was
emoved from the freezer, reconstituted in 0.25 ml  sterile water,
nd re-evaluated in the MAC-ELISA. The VSAA of the lyophilized
ntigen decreased slightly compared to non-lyophilized antigen,
ut the working antigen dilution remained at 1:40 (Table 2B).
.3. SINV/EEEV evaluationPerformance of inactivated SINV/EEEV cell culture and EEEV
MB  antigens was compared in a panel of 12 previously identiﬁed
EEV positive serum samples (Table 3). All results were positive in
able 3
omparison of SINV/EEEV cell culture and EEEV SMB  antigen reactivity in the EEEV
AC-ELISA.
EEEV positive serum sample SINV/EEEV cell culture
antigen – P/N
EEEV SMB  antigen –
P/N
High positive 1 49.3 47.6
High positive 2 61.4 74.5
High positive 3 63.1 87.9
High positive 4 56.2 53.3
Medium positive 1 54.5 62.7
Medium positive 2 54.5 53.0
Medium positive 3 46.2 32.8
Medium positive 4 53.5 41.1
Low  positive 1 4.9 1.2
Low  positive 2 12.3 3.5
Low  positive 3 4.9 1.8
Low  positive 4 12.8 4.7
/N, positive-to-negative ratio.
AC-ELISA interpretations: P/N < 2 = negative, P/N 2–3 = equivocal, P/N > 2 = positive.ical Methods 223 (2015) 19–24 23
the MAC-ELISA using the SINV/EEEV antigen, and P/Ns were higher
in 9 of 12 samples compared to EEEV SMB  antigen. Two of the
low-positive samples (samples 1 and 3) had negative results in the
MAC-ELISA with the EEEV SMB  antigen.
4. Discussion
EEEV is an enzootic arbovirus that circulates throughout east-
ern North America. Although only a few cases of EEEV infections
in humans and unvaccinated horses are reported annually, EEEV
infection is clinically indistinguishable from other neuroinvasive
diseases and detection relies on laboratory-based surveillance. The
EEEV MAC-ELISA is the primary serological test used to detect EEEV
infection, conﬁrmed by the neutralization assay with live virus.
Viral antigens used in the ELISA generally are made from inactiv-
ated and concentrated live virus. EEEV is a select agent restricted,
BSL-3 agent; therefore in order to make EEEV antigen from wild-
type EEEV, a laboratory would need to have a BSL-3 facility and be
registered with the select agent program.
SINV/EEEV is a recombinant virus in which the genes coding
for the antigenic EEEV envelope proteins have replaced those of
SINV in the SINV genome. SINV/EEEV can be used under BSL-2
conditions and is not under select agent restrictions. Previously,
SINV/EEEV was shown to be neutralized similarly to wild-type
EEEV in the PRNT (Johnson et al., 2011). Production of EEEV anti-
gen from SINV/EEEV needed to be assessed to determine if the
antigen would react appropriately to EEEV IgM in the MAC-ELISA,
and to evaluate the stability of the chimeric virus particle proteins
throughout the antigen production process of inactivation, concen-
tration, and lyophilization. Using a previously described antigen
production algorithm, the antigen production process and evalu-
ation of SINV/EEEV in the MAC-ELISA, the end-use assay for this
study, were described here (Goodman et al., 2014).
Peak SINV/EEEV titers from the growth curves were similar in
all cell types, between 8 and 9 log10 PFU/ml, but none of the super-
natant aliquots yielded acceptable VSAA in the EEEV MAC-ELISA.
This lack of antigen activity prior to inactivation, and up to a tenfold
increase in activity after inactivation, had been observed previ-
ously (French and McKinney, 1964; Goodman et al., 2014). Future
experiments to investigate this include possible epitope mapping
and X-ray crystallography to determine why there is a difference
in antigen activity between infectious versus inactivated material.
Therefore, production continued with inactivation by BPL at con-
centrations ranging from 0.1% to 0.3%. SINV/EEEV was completely
inactivated by ≥0.2% BPL, and although the VSAA was acceptable,
the NBR was high, and increased to unacceptable levels after the
antigen was concentrated 12×.
The increase in NBR following BPL treatment has been observed
previously (Goodman et al., 2014). BPL is hydrolyzed in aqueous
solution to -hydroxypropionic acid (Perrin and Morgeaux, 1995).
Sodium bicarbonate is added to the supernatant throughout the
24 h inactivation process to neutralize the acid and preserve the
VSAA, as acidity degrades the protein. In order to determine if
there was  residual BPL in the supernatant that might be causing
the increase in NBR following BPL inactivation, the supernatant
was incubated at 37 ◦C for 2 h to facilitate complete BPL hydrol-
ysis, even though it had previously been shown that some VSAA
is destroyed during hydrolysis, probably due to the rapid acidiﬁca-
tion of the supernatant heated to 37 ◦C (Goodman et al., 2014). As
expected, the VSAA of the SIN/EEEV did decrease following hydrol-
ysis of the BPL. However, in contrast to previous observations, the
NBR increased. Chemical inactivation with BPL is inexpensive and
effective, but the quality of the ﬁnal product is highly variable
(Goodman et al., 2014). Therefore, BPL was not considered to be
an acceptable method for inactivating SINV/EEEV because of the
resultant high NBR.
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Gamma  irradiation is an alternative method of virus inacti-
ation. At 6 Mrad, SINV/EEEV was completely inactivated, had
igher VSAA compared to live virus, and lower NBR compared to
PL-inactivated antigen. Further processing by concentration and
yophilization did not alter the performance of the antigen in the
nd-use MAC-ELISA.
Comparison of SINV/EEEV cell culture antigen to EEEV SMB
ntigen using previously identiﬁed EEEV positive control serum
amples demonstrated the acceptable performance of SINV/EEEV
ntigen in the EEEV MAC-ELISA. Indeed the sensitivity of the EEEV
AC-ELISA was higher when the SINV/EEEV antigen was used, as
gM was detected in 2 low positive samples with the SINV/EEEV
ntigen, but not the EEEV SMB  antigen.
In conclusion, EEEV antigen used in the diagnostic MAC-ELISA
ould be produced from SINV/EEEV under optimized conditions
etermined empirically. The ﬁnal product derived from the recom-
inant SINV/EEEV had similar antigenicity and stability to antigen
roduced from wild-type alphaviruses (Goodman et al., 2014). The
bility of non-select agent registered, BSL-2 laboratories to pro-
uce inactivated EEEV antigen by using recombinant SINV/EEEV
ill enhance the capacity of reference laboratories to provide these
mportant diagnostic reagents.
cknowledgments
We  would like to thank Lyle Petersen, Wendi Kuhnert, Paul
impson, and Kathi Kellar for their exceptional assistance in coor-
inating gamma-irradiation services between CDC-Fort Collins, CO
nd CDC-Atlanta, GA.
eferences
guilar, P.V., Robich, R.M., Turell, M.J., O’Guinn, M.L., Klein, T.A., Huaman, A.,
Guevara, C., Rios, Z., Tesh, R.B., Watts, D.M., Olson, J., Weaver, S.C., 2007.
Endemic eastern equine encephalitis in the Amazon region of Peru. Am.  J. Trop.
Med. Hyg. 76, 293–298.
rrigo, N.C., Watts, D.M., Frolov, I., Weaver, S.C., 2008. Experimental infection of
Aedes sollicitans and Aedes taeniorhynchus with two  chimeric sindbis/eastern
equine encephalitis virus vaccine candidates. Am.  J. Trop. Med. Hyg. 78, 93–97.
asile, A.J., Horiuchi, K., Panella, A.J., Laven, J., Kosoy, O., Lanciotti, R.S.,
Venkateswaran, N., Biggerstaff, B.J., 2013. Multiplex microsphere
immunoassays for the detection of IgM and IgG to arboviral diseases. PLOS
ONE 8, 1–16.
eaty, B., Calisher, C., Shope, R., 1995. Arboviruses. In: Lennette, E., Lennette, D.,
Lennette, E. (Eds.), Diagnostic Procedures for Viral, Rickettsial, and Chlamydial
infections. American Public Health Association, Washington, DC, pp. 189–212.ical Methods 223 (2015) 19–24
Brault, A.C., Powers, A.M., Chavez, C.L., Lopez, R.N., Cachon, M.F., Gutierrez, L.F.,
et  al., 1999. Genetic and antigenic diversity among eastern equine encephalitis
viruses from North, Central, and South America. Am. J. Trop. Med. Hyg. 61,
579–586.
Franklin, R.P., Kinde, H., Jay, M.T., Kramer, L.D., Green, E.G., Chiles, R.E., et al., 2002.
Eastern equine encephalomyelitis virus infection in a horse from California.
Emerg. Infect. Dis. 8, 283–288.
French, G.R., McKinney, R.W., 1964. Use of beta-propiolactone in preparation of
inactivated arbovirus serologic test antigens. J. Immunol. 92,
772–778.
Goodman, C.H., Russell, B.J., Velez, J.O., Laven, J.J., Nicholson, W.L., Bagarozzi Jr.,
D.A., Moon, J.L., Bedi, K., Johnson, B.W., 2014. Development of an algorithm for
production of inactivated arbovirus antigens in cell culture. J. Virol. Methods
208,  66–78.
Grifﬁn, D.E., 2001. Alphaviruses. In: Knipe, D.M., Howley, P.M. (Eds.), Fields
Virology. , 4th ed. Lippincott, Williams, and Wilkins, New York, NY, pp.
917–962.
Johnson, B.W., Kosoy, O., Wang, E., Delorey, M.,  Russell, B., Bowen, R.A., Weaver,
S.C.,  2011. Use of sindbis/eastern equine encephalitis chimeric viruses in
plaque reduction neutralization tests for arboviral disease diagnostics. Clin.
Vacc. Immun. 18, 1486–1491.
Lambert, A.J., Martin, D.A., Lanciotti, R.S., 2003. Detection of North American
eastern and western equine encephalitis viruses by nucleic acid ampliﬁcation
assays. J. Clin. Microbiol. 41, 379–385.
Martin, D.A., Muth, D.A., Brown, T., Johnson, A.J., Karabatsos, N., Roehrig, J.T., 2000.
Standardization of immunoglobulin M capture enzyme-linked immunosorbent
assays for routine diagnosis of arboviral infections. J. Clin. Microbiol. 38,
1823–1826.
Morris, C.D., 1988. Eastern equine encephalomyelitis. In: Monath, T.P. (Ed.), The
Arboviruses: Epidemiology and Ecology III. CRC Press, Boca Raton, FL, pp.
293–298.
Perrin, P., Morgeaux, S., 1995. Inactivation of DNA by -propiolactone. Biologicals
23,  207–211.
Powers, A., Huang, H., Roehrig, J., Strauss, E., Weaver, S., 2012. Part II – the positive
sense single stranded RNA viruses: Togaviridae: alphavirus. In: King, A.M.Q.,
Adams, M.J., Carstens, E.B., Lefkowitz, E.J. (Eds.), Virus Taxonomy: Classiﬁcation
and Nomenclature of Viruses: Ninth Report of the International Committee on
Taxonomy of Viruses. Elsevier Academic Press, San Diego, CA,
pp.  1105–1110.
Tsai, T.F., Weaver, S.C., Monath, T.P., 2002. Alphaviruses. In: Richmann, D.D.,
Whitley, R.J., Hayden, F.G. (Eds.), Clinical Virology. ASM Press, Washington, DC,
pp. 1177–1210.
Villari, P., Spielman, A., Komar, N., McDowell, M.,  Timperi, R.J., 1995. The economic
burden imposed by a residual case of eastern encephalitis. Am. J. Trop. Med.
Hyg. 52, 8–13.
Wang, E., Petrakova, O., Adams, A.P., Aguilar, P.V., Kang, W.,  Paessler, S., Volk, S.M.,
Frolov, I., Weaver, S.C., 2007. Chimeric sindbis/eastern equine encephalitis
vaccine candidates are highly attenuated and immunogenic in mice. Vaccine
25,  7573–7581.
Weaver, S.C., 2001. Eastern equine encephalitis. In: Service, M.W.  (Ed.), The
Encyclopedia of Arthropod-Transmitted Infections. CAB International,
Wallingford, UK, pp. 151–159.
Weaver, S.C., Tesh, R.B., Shope, R.E., 1999. Alphavirus infections. In: Guerrant, R.I.,
Walker, D.H., Weller, P.F. (Eds.), Tropical Infectious Diseases Principles,
Pathogens and Practice. Churchill Livingstone, Philadelphia, PA,
pp. 1281–1287.
